ArticlePediatrics2023
Buprenorphine Dispensing Among Youth Aged ≤19 Years in the United States: 2015-2020.
Article in Pediatrics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.
- Evidence Base on Outpatient Behavioral Treatments for Adolescent Substance Use, Update 2018-2023: Current Status, Best Practices, and Opportunities for Advancing the Science.Journal of clinical child and adolescent psychology : the official journal for the Society of Clinical Child and Adolescent Psychology, American Psychological Association, Division 53Pooled it
- Opioid Use Disorder and Evidence-Based Care Among Medicaid-Enrolled Youths.JAMA network open · 2026Article
- Adolescent Substance Use Screening in the Emergency Department.Journal of the American College of Emergency Physicians open · 2026Review
- Prevention and Management of Opioid use Disorder and Overdose in Adolescents and Young Adults.Current psychiatry reports · 2025Review
- Adolescent Treatment Landscape of Depression, Suicidality, and Substance Use Disorder in the US.JAMA health forum · 2025Article
- Ethical Considerations in Substance Use Treatment for Youth: Assessing Clinical Practices and Policy Frameworks for Potential Harm.Research on child and adolescent psychopathology · 2025Review
- Substance Use Screening, Brief Intervention, and Referral to Treatment Among Youth-Serving Clinicians.JAMA network open · 2025Article
- Article
- Opportunities to enhance retention on medication for opioid use disorder for adolescents and young adults: results from a qualitative study with medical providers in Philadelphia, PA.Harm reduction journal · 2024Article
- Emergency department management of opioid use disorder in pediatric patients.Journal of the American College of Emergency Physicians open · 2024Article
- Clinician Willingness to Prescribe Medications for Opioid Use Disorder to Adolescents in Indiana.JAMA network open · 2024Article
- Association Between Cost-Sharing and Buprenorphine Prescription Abandonment.Journal of general internal medicine · 2024Article
- Article
- A case of severe opioid and methamphetamine use disorder in a 14 year old.Addiction science & clinical practice · 2024Article
- Medication Treatment for Youth in Substance Use Disorder Residential Treatment.Journal of attention disorders · 2024Article
- Substance Use Patterns and Characteristics Using Real World Data from Adolescents Assessed for Substance Use and Treatment Planning-United States, 2017-2021.Substance use & misuse · 2024Article
- Opioid use disorder medications among youth in primary care: Subgroup analysis of the PROUD trial.Pediatrics open scienceArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
BACKGROUND AND
objectivesOpioid related overdose among adolescents and young adults in the United States is rising. Medications for opioid use disorder (MOUD), including buprenorphine can reduce the risk of overdose, however they are underutilized. A better understanding of buprenorphine prescribing to youth will help inform interventions to expand access to treatment.
methodsWe used IQVIA data to examine buprenorphine dispensing trends among youth aged ≤19 years from 2015 to 2020. Dispensing was examined by prescriber specialty, age, and sex. Data were weighted to provide national estimates.
resultsThe rate of buprenorphine dispensed to youth decreased 25% over the study period, from 0.84 to 0.63 prescriptions per 1000 youth per year. The proportion of youth dispensed buprenorphine also decreased 45%, from 7.6 to 4.2 persons per 100 000 per year. Over the same time, the proportion of adults aged ≥20 years dispensed buprenorphine increased 47%, from 378 to 593 persons per 100 000. Differences in dispensing by sex and temporal trends were also noted. Pediatricians accounted for less-than 2% of all prescriptions dispensed.
conclusionsBuprenorphine dispensing to youth is low and declining in recent years. Given rates of opioid use disorder among youth, these findings suggest that many youth who could benefit from MOUD are not receiving it. Pediatricians could play a role in expanding access to MOUD for this high-risk population. Efforts to expand access to MOUD for adolescents could include improving training in opioid use disorder treatment of pediatricians and encouraging all clinicians who care for adolescents and young adults to obtain waivers to prescribe buprenorphine for MOUD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.